IXAZOMIB CITRATE

IUPAC name:

2-[4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid

CAS No.

1239908-20-3

Molecular Weight:

517.1g.mol−1

Molecular Formula:

C20H23BCl2N2O9

Granule:

Mechanism Of Action:

Ixazomib functions by obstructing protein degradation through the inhibition of the 20S catalytic subunit of the 26S proteasome. Specifically, at lower concentrations, MLN2238 targets and inhibits the β5 chymotrypsin-like subunit, which is responsible for cleaving proteins after hydrophobic residues. This mechanism effectively hinders the proteasome’s ability to degrade proteins

Indication:

Multiple Myeloma

Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma that has been previously treated with at least one prior therapy. This combination therapy has been designated as an orphan drug for this specific use.

information

Category: Oncology

January 21, 2024

Desloratadine

Anti-Histamine

Cas No: 100643-71-8

Mechanism Of Action: Desloratadine is a non-sedating, long-acting antihistamine that selectively blocks peripheral histamine H1-receptors. It is the major active metabolite of loratadine and works

Voriconazole

Anti-Microbial

Cas No: 137234-62-9

Mechanism Of Action: Voriconazole is a triazole antifungal agent that works by inhibiting the fungal cytochrome P450 enzyme 14-alpha-lanosterol demethylase1. This enzyme is crucial for

Enoxaparin Sodium

Cardiovascular

Cas No: 679809-58-6

Mechanism Of Action: Enoxaparin, a low molecular weight heparin (LMWH), works primarily by activating antithrombin III, which in turn inhibits factor Xa and IIa (thrombin).

Tirzapatide

Anti-Diabetic

Cas No: 2023788-19-2

Mechanism Of Action : Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This means it mimics the

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1